LAUSR: cd19 cd20

CD19/CD20‐REDIRECTED BISPECIFIC CAR T CELL TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Patients with systemic lupus erythematosus show increased proportions of CD19+CD20− B cells and secretion of related autoantibodies

Sign Up to like & get
recommendations!
1 Published in 2020 at "Clinical Rheumatology"

DOI: 10.1007/s10067-020-05220-2

Abstract: Background At present, anti-CD20 monoclonal antibody treatments targeting systemic lupus erythematosus (SLE) are complex, variable, and often have disappointing outcomes. High levels of programmed cell death-1 (PD-1) and its ligands (PD-L1, PD-L2) or CD80/CD86 on… read more here.

Keywords: cd20 cells; sle patients; cd19 cd20; systemic lupus ... See more keywords

P167 Overcoming rituximab resistance in autoimmune disease: back to basics

Sign Up to like & get
recommendations!
2 Published in 2023 at "Rheumatology"

DOI: 10.1093/rheumatology/kead104.208

Abstract: Previous research into B cell biomarkers of poor response to the anti-CD20 drug rituximab in autoimmune disease relates to insufficient B cell depletion. Expansion of memory B cell (MBC) subsets were also associated with poorer… read more here.

Keywords: autoimmune disease; cd19 cd20; none; rituximab ... See more keywords

OP0356 Plasmablast proliferation is associated with toll like receptor 7 polymorphisms and upregulation of type i interferon, contributing to the antibody production in antiphospholipid syndrome

Sign Up to like & get
recommendations!
0 Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.2816

Abstract: Background Antiphospholipid antibodies (aPL) as pathogenic autoantibodies in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are supported by a number of clinical, ex vivo and animal studies. Nevertheless, aPL are not eliminated by corticosteroid… read more here.

Keywords: toll like; antiphospholipid syndrome; aps patients; production ... See more keywords

Abstract CT007: CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas

Sign Up to like & get
recommendations!
1 Published in 2021 at "Clinical Trials"

DOI: 10.1158/1538-7445.am2021-ct007

Abstract: 50% of patients with relapsed/refractory (R/R) B-cell lymphomas (BCL) who initially respond to CD19 CAR T therapy will relapse either due to poor CAR-T persistence or CD19 antigen escape. Preclinical data demonstrate that engineering of… read more here.

Keywords: cd19 cd20; car; cell; bispecific ... See more keywords

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Sign Up to like & get
recommendations!
1 Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-129600

Abstract: Background: CD19 and CD20 are B-cell lineage-specific antigens expressed on the cell surface of most B-cell lymphomas. While CD20 is acquired during late stages of B-cell lymphogenesis and is then lost upon differentiation into plasma… read more here.

Keywords: cd19 cd20; expression; cd20; cell ... See more keywords

Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL

Sign Up to like & get
recommendations!
1 Published in 2020 at "Blood"

DOI: 10.1182/blood-2020-140154

Abstract: CD20 targeted therapy by means of anti-CD20 mAb is currently the most important regimen for treating B cells malignancies. However, 1-2% of B-cell lymphoma patients test negative for CD20. Besides, it has been reported in… read more here.

Keywords: cd3; cd19 cd20; cd20; cell ... See more keywords

LAUSR

You are not signed in:

Sign Up!